[Difficulties in controlled inhalation of alpha 1-protease inhibitor].
In this paper a number of studies will be summarized which were designed to improve the inhalation of alpha 1 -protease inhibitor in patients with alpha 1-protease inhibitor deficiency. A pilot study has shown that the high inter-individual variability of drug deposition in the lungs is due to heterogeneous breathing patterns of the patients. Controlling the breathing pattern led to a significantly decreased variability. Then it was studied which particle size and breathing pattern resulted in highest peripheral lung deposition in patients with emphysema. It was found that for 3 - 4 microm particles and slow inhalation flow rate the peripheral deposition increases with increasing inhalation volume. After the development of an inhalation device which allows to perform controlled inhalations in clinical practice it was shown that this device, in combination with a breathing pattern individually normalized to the patients lung function, allows to deposit nearly 60 % of the drug into the patients lung periphery.
Brand
P
P
Klinische Kooperationsgruppe Aerosolmedizin des GSF-Institutes für Inhalationsbiologie, Gauting.
Maas Enriquez
M
M
Meyer
T
T
Scheuch
G
G
Weber
N
N
D000280:Administration, Inhalation; D004646:Emphysema / Q000188:drug therapy; D015842:Serine Proteinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000515:alpha 1-Antitrypsin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019896:alpha 1-Antitrypsin Deficiency / Q000188:drug therapy*
D015842:Serine Proteinase Inhibitors; D000515:alpha 1-Antitrypsin